Bristol Myers Squibb and ONO Pharmaceutical Co., Ltd.

Compendium of presentations
Click on a tumor type to view related presentations

**Table of Contents**

<table>
<thead>
<tr>
<th>Acute Myeloid Leukemia</th>
<th>Advanced Solid Tumors</th>
<th>Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Cancer</td>
<td>Genitourinary Cancer</td>
<td>Head &amp; Neck Cancer</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>Lymphoma</td>
<td>Melanoma</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>Myelodysplastic Syndromes</td>
<td></td>
</tr>
</tbody>
</table>
## Acute Myeloid Leukemia

### Oral Presentation

**Abstract #7501:** Enasidenib (ENA) plus azacitidine (AZA) significantly improves complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)

**Lead Author and Presenter:** Courtney D. DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

### Poster Discussion Presentation

**Abstract #7513:** Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: results from the phase III QUAZAR® AML-001 maintenance trial

**Lead Author and Presenter:** Hartmut Döhner, Ulm University Hospital, Ulm, Germany

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

### Poster Presentations

**Abstract #7530:** CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: results from the phase III QUAZAR® AML-001 maintenance trial

**Lead Author and Presenter:** Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**Abstract #7533:** Health-related quality of life in the phase III QUAZAR® AML-001 maintenance trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia in first remission following induction chemotherapy

**Lead Author and Presenter:** Gail J. Roboz, Weill Cornell Medical College; New York Presbyterian Hospital, New York, NY, USA

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #3058: First-in-human phase 1 study of BMS-986249 monotherapy and in combination with nivolumab in advanced cancer

Lead Author and Presenter: Martin Gutierrez, Hackensack University Medical Center, Hackensack, NJ, USA

Session: Developmental Therapeutics—Immunotherapy

Abstract #TPS604: A phase 3 trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL

Lead Author and Presenter: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Session: Breast Cancer—Local/Regional/Adjuvant

Abstract #TPS1105: A phase 2 trial of nivolumab + palbociclib + anastrozole in postmenopausal women and men with ER+/HER2− primary breast cancer: CheckMate 7A8

Lead Author and Presenter: Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA, USA

Session: Breast Cancer—Metastatic
# Gastrointestinal Cancer

## Poster Discussion Presentation

**Abstract #4515**: Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): outcomes by geographic region  
**Lead Author**: Michele Reni, IRCCS Ospedale, San Raffaele Scientific Institute, Milan, Italy  
**Presenter**: Margaret Tempero, University of California, San Francisco, San Francisco, CA, USA  
**Session**: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

## Poster Presentations

**Abstract #4040**: Nivolumab + low-dose ipilimumab as first-line therapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 2-year clinical update  
**Lead Author and Presenter**: Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA  
**Session**: Gastrointestinal Cancer—Colorectal and Anal

**Abstract #4618**: Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial  
**Lead Author**: Michele Reni, IRCCS Ospedale, San Raffaele Scientific Institute, Milan, Italy  
**Presenter**: Margaret Tempero, University of California, San Francisco, San Francisco, CA, USA  
**Session**: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
## Oral Presentations

**Abstract #5007**: FRACTION-RCC: innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma  
**Lead Author and Presenter**: Toni K. Choueiri, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA  
**Session**: Genitourinary Cancer—Kidney and Bladder

**Abstract #5009**: Biomarker analyses from the phase 3 CheckMate 214 trial of nivolumab plus ipilimumab or sunitinib in advanced renal cell carcinoma  
**Lead Author and Presenter**: Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY, USA  
**Session**: Clinical Science Symposium, Updates on Immunotherapy Biomarkers Development in Kidney and Bladder Cancers

## Poster Presentations

**Abstract #TPS5090**: A phase 2, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guérin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT  
**Lead Author and Presenter**: Noah M. Hahn, Johns Hopkins School of Medicine, Baltimore, MD, USA  
**Session**: Genitourinary Cancer—Kidney and Bladder

**Abstract #TPS5091**: A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle-invasive bladder cancer (MIBC)  
**Lead Author and Presenter**: Guru Sonpavde, Dana-Farber Cancer Institute, Boston, MA, USA  
**Session**: Genitourinary Cancer—Kidney and Bladder

**Abstract #TPS5099**: A phase 3, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk of relapse after radical or partial nephrectomy (CheckMate 914)  
**Lead Author and Presenter**: Axel Bex, The Netherlands Cancer Institute, Amsterdam, Netherlands, and Division of Surgical and Interventional Science, Royal Free London NHS Foundation Trust, University College London, London, UK  
**Session**: Genitourinary Cancer—Kidney and Bladder
## Head & Neck Cancer

### Poster Presentation

**Abstract #6532**: HANNA – real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany  
**Lead Author and Presenter**: Andreas Dietz, University Hospital Leipzig, Leipzig, Germany  
**Session**: Head and Neck Cancer

## Lung Cancer

### Oral Presentations

**Abstract #9500**: Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1  
**Lead Author and Presenter**: Suresh S. Ramalingam, Winship Cancer Institute, Emory University, Atlanta, GA, USA  
**Session**: Lung Cancer—Non-Small Cell Metastatic

**Abstract #9501**: Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemotherapy as first-line treatment for stage IV/recurrent NSCLC: CheckMate 9LA  
**Lead Author and Presenter**: Martin Reck, Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany  
**Session**: Lung Cancer—Non-Small Cell Metastatic

### Poster Presentations

**Abstract #9560**: Nivolumab plus ipilimumab with 2 cycles of chemotherapy in first-line metastatic non-small cell lung cancer: CheckMate 568 Part 2  
**Lead Author and Presenter**: Justin F. Gainor, Massachusetts General Hospital, Boston, MA, USA  
**Session**: Lung Cancer—Non-Small Cell Metastatic

**Abstract #TPS9076**: CheckMate 77T: a phase 3 trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC  
**Lead Author and Presenter**: Tina Cascone, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  
**Session**: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
### Oral Presentation

**Abstract #3501:** Phase 1/2 study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL  
**Lead Author and Presenter:** Neha Mehta-Shah, Washington University School of Medicine, St Louis, MO, USA  
**Session:** Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

### Poster Discussion Presentation

**Abstract #8013:** Nivolumab and brentuximab vedotin–based, response-adapted treatment in children, adolescents, and young adults with standard-risk relapsed/refractory classical Hodgkin lymphoma: primary analysis  
**Lead Author and Presenter:** Peter D. Cole, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA  
**Session:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

### Poster Presentations

**Abstract #8037:** Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)  
**Lead Author and Presenter:** Carlos Bachier, Sarah Cannon Blood Cancer Network, Nashville, TN, USA  
**Session:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**Abstract #8040:** Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): updated results from the PILOT study  
**Lead Author and Presenter:** Alison Sehgal, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA  
**Session:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**Abstract #8046:** MAGNIFY: phase IIIb interim analysis of induction R² followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma  
**Lead Author and Presenter:** David Jacob Andorsky, Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO, USA  
**Session:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
### Poster Discussion Presentation

**Abstract #10019:** CheckMate 067: long-term outcomes in patients with mucosal melanoma  
**Lead Author and Presenter:** Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center, New York, NY, USA  
**Session:** Melanoma/Skin Cancers

### Poster Presentation

**Abstract #10043:** Estimating treatment-free survival over extended follow-up in patients with advanced melanoma treated with immune checkpoint inhibitors: 5-year follow-up of CheckMate 067  
**Lead Author and Presenter:** Meredith M. Regan, Dana-Farber Cancer Institute, Boston, MA, USA  
**Session:** Melanoma/Skin Cancers
Multiple Myeloma

**Oral Presentations**

**Abstract #8500:** First-in-human phase 1 study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

**Lead Author and Presenter:** Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA, USA

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Abstract #8503:** Idecabtagene vilucel (ide-cel; bb2121), a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results

**Lead Author and Presenter:** Nikhil C. Munshi, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Abstract #8504:** Orvacaabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)

**Lead Author and Presenter:** Sham Mailankody, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Poster Discussion Presentation**

**Abstract #8518:** Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: results from the Connect®MM Registry

**Lead Author and Presenter:** Sikander Ailawadhi, Mayo Clinic, Jacksonville, FL, USA

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Poster Presentations**

**Abstract #8525:** KarMMA-RW: a study of real world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMA

**Lead Author and Presenter:** Sundar Jagannath, Mount Sinai Hospital, New York, NY, USA

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Abstract #8531:** Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM)

**Lead Author and Presenter:** Lilly Wong, Bristol Myers Squibb, Princeton, NJ, USA

**Session:** Hematologic Malignancies—Plasma Cell Dyscrasia
# Myelodysplastic Syndromes

## Poster Discussion Presentation

**Abstract #7518:** Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS)

**Lead Author and Presenter:** Rami S. Komrokji, Moffitt Cancer Center, Tampa, FL, USA

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

## Poster Presentations

**Abstract #7553:** Molecular diagnostic testing patterns in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect® MDS/AML disease registry

**Lead Author and Presenter:** Tracy I. George, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**Abstract #7554:** Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study

**Lead Author and Presenter:** Amer Zeidan, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA

**Session:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

© 2020 Bristol-Myers Squibb Company 05/20 VV-MED-01694

This booklet may represent investigational, unapproved uses of some products listed. The safety and efficacy of the agents and/or uses under investigation have not been established, and there is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. This compilation of presentations is intended as an educational resource and is for the exchange of scientific data with clinical investigators and health care professionals.